Israel and Pfizer have signed a historic agreement that allows Israel to receive millions of Pfizer-BioNTech COVID-19 vaccine doses over the next decade. The deal is worth over 1 billion dollars, and it marks one of the most significant collaborations between a country and a pharmaceutical company.
The agreement was announced by Prime Minister Naftali Bennett and a team of executives from Pfizer and BioNTech. Under the terms of the agreement, Israel will receive 8 million vaccine doses in 2022, with an option to purchase an additional 8 million doses, bringing the total to 16 million. Israel will also receive millions of doses in each of the following years, up to 2024. The deal includes an initial purchase of 2 million doses in the fourth quarter of this year.
The agreement is aimed at supporting the ongoing vaccination campaign in Israel, which has emerged as a global leader in vaccinating its population. As of August 2021, over 60% of the population in Israel had received at least one dose of the vaccine, and more than 55% had received two doses. The country has also started offering a third booster dose to people over 60 years old, making it the first country to do so.
The deal is a significant boost to Pfizer, which has been one of the leading pharmaceutical companies in the COVID-19 vaccine race. The company`s vaccine has been authorized for emergency use in many countries, including Israel, and has been shown to be highly effective in preventing severe illness and hospitalization.
The agreement is also a significant milestone for Israel, which has been praised for its vaccination campaign. The country has seen a significant drop in COVID-19 cases and hospitalizations since the start of the campaign, and it has been hailed as a model for other countries.
The agreement has been widely praised by Israeli officials, who have hailed it as a sign of the country`s commitment to fighting the pandemic. It is also seen as a sign of the close relationship between Israel and Pfizer, which has been developing new drugs and therapies in partnership with Israeli companies for many years.
In conclusion, the Israel-Pfizer agreement is an important development in the ongoing fight against COVID-19. It represents a significant investment in the country`s vaccination campaign and shows the continued commitment of Israel and Pfizer to working together to fight the pandemic. The deal is a notable milestone in the efforts of the global community to bring an end to the pandemic, and it provides hope for a better future for all.